This site uses own and third-party cookies to offer a better service. If you continue browsing we will consider you accepting its use.

Design of emulsifiers to produce safe, controlled and reliable novel stimuli-responsive nanocapsules for skin care applications

PeptiCaps is funded by the European Union Framework Programme for Research and Innovation Horizon 2020. The objective of this three-year long project is to develop and validate a new family of safe stimuli-responsive nanocapsules designed to encapsulate fragile active ingredients, either hydrophilic or hydrophobic, as cosmetic ingredient.

4 different skin conditions, i.e. irritant contact dermatitis, allergic contact dermatitis, skin photo-damage and skin pigmentation which are affecting high percentage of the population, will be considered during the project.

PeptiCaps technology will take advantage of the physico-chemical changes induced by the skin condition (change of pH and presence of enzymes) to release the active ingredients in the desired location.

Nanocapsules will be produced at pilot plant scale using industrially relevant processes, such as high pressure homogenizer and tubular membrane contactor.

Full physico-chemical characterization and (eco)toxicity of the nanocapsules will be assessed to validate the nanocapsules as new, safe and smart cosmetic ingredient.


During the project PeptiCaps´team will work to achieve different objectives:

  • Skin conditions.
  • Scientific objectives.


PeptiCaps will last 36 months. The work plan has been divided in 6 Work Packages including:

  • Research, Technology and Development (RTD).
  • Management (MGT).
  • Validation (VAL).


PeptiCaps consortium consists of 9 partners from 5 Member States:

  • 4 SMEs: Ahava Dead Sea Laboratories LTD, Polypeptide Therapeutic Solutions SL, Spinverse, Angel Consulting.
  • 5 Research organizations: IK4-CIDETEC, Université de Bordeaux, Universidad del País Vasco/Euskal Herriko Unibertsitatea, Université Claude Bernard Lyon I, Istituto di Ricerche Farmacologiche Mario Negri.